Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$957.00 USD
+19.39 (2.07%)
Updated May 3, 2024 04:00 PM ET
After-Market: $958.14 +1.14 (0.12%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
REGN 957.00 +19.39(2.07%)
Will REGN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REGN
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Other News for REGN
Buy Rating Affirmed for Regeneron on Strong Product Sales and Promising Pipeline
Wall Street Breakfast: The Week Ahead
Goldman’s top 50 Strong Balance Sheet stocks
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
Amgen Could Become A Real Contender In The Obesity Market